Effect of valsartan on renal function in patients with hypertension and stable renal insufficiency

Abstract

Angiotensin II AT 1 receptor blockers have been introduced into clinical practice; however, larger-scale information on their tolerability and effects on renal function in patients with hypertension and renal insufficiency is limited. A 6-month, double-masked, placebo-controlled, multicenter, clinical trial was performed to address this issue. Fifty-six adults with hypertension and reduced renal function were studied. They received the AT 1 receptor blocker valsartan (80 mg/d) or placebo, in addition to other antihypertensive drugs. The renal variables studied were glomerular filtration rate, effective renal plasma flow, renal blood flow, serum creatinine level, and 24-hour urinary albumin, protein, and urea excretion. Drug tolerability was also assessed. Differences were not significant between the valsartan and placebo groups with respect to effects on any renal function variable. Furthermore, the tolerability of valsartan and placebo was not different. Compared with placebo, valsartan lowered systolic and diastolic blood pressures. Data from this study suggest that valsartan is well tolerated and effective in treating patients with hypertension and reduced renal function.